GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 74 1. Ratio of Remuneration of Non-Executive Directors to the median remuneration of the employees of the Company for the financial year ended 31 March 2022. Sr no Name of Directors Designation Ratio to Median Remuneration 1 Ms. R. S. Karnad Chairperson, Non-Executive Director 2.15 2 Mr. P. V. Bhide Independent Director 1.65 3 Mr. N. Kaviratne Independent Director 1.76 4 Dr (Ms.). S. Maheshwari Independent Director 1.40 5 Mr. A. N. Roy Independent Director 1.40 6 Mr. D. Sundaram Independent Director 1.76 2. Ratio of Remuneration of Whole-time Directors & Key Managerial Personnel (KMP) against the Company. Sr no Whole-time Directors & KMP Designation Ratio to median Remuneration (%) Increase in remuneration in the financial year 1 S. Venkatesh Managing Director 71.54 8.03% 2 Ms. P. Thakur Whole-time Director & CFO 35.08 10.6% 3 A. Nadkarni Company Secretary 10.73 8.24%* 3. There was 25.37%** increase in the median remuneration of employees. 4. There were 3840 permanent employees on the rolls of the Company as on 31 March, 2022. 5. Average percentile increases already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof: The average percentage increase made in the salaries of employees and managerial personnel was 8% in 2021-22 in line with market and business growth. 6. We affirm that the remuneration paid to Directors, Key Managerial Personnel and other Employees is as per the Remuneration Policy of the Company. On behalf of the Board of Directors Ms. R. S. Karnad Mumbai, 16 May, 2022 Chairperson *Excluding one-time market correction **Higher median in 2021 is on account of implementing the Long-term Settlement signed with unions for increase in salary of Medical Business Associates which was due for renewal from October 2019 and was paid with arrears. This settlement is valid till September 2023. ANNEXURE ‘F’ to the Directors Report Disclosure under Section 197 (12) of the Companies Act, 2013 and other disclosures as per Rule 5 of the Companies (Appointment & Remuneration of Key Managerial Personnel) Rules, 2014